Taurine — evidence review

• Lower clinic and ambulatory systolic and diastolic blood pressure.
• Lower resting heart rate.
• Better left-ventricular ejection fraction and lower NYHA class in heart failure.
• Better exercise capacity in heart-failure patients.
• Better endurance (time-to-exhaustion, time-trial).
• Better VO₂max / aerobic capacity.
• Better strength, power, or jump.
• Less exercise-induced oxidative stress / faster recovery.
• Lower fasting glucose, HbA1c, fasting insulin, HOMA-IR.
• Lower triglycerides, total cholesterol, LDL.

Isolated oral taurine has **human RCT-level support for modest reductions in blood pressure and for small improvements in several cardiometabolic surrogates (fasting glucose, TG, LDL, HOMA-IR), with a weaker, older, smaller file for NYHA / LVEF / exercise capacity in heart failure.** The BP effect is the most consistent: on the order of **3–4 mm Hg SBP** in metas, and **~4–5 mm Hg extra clinic SBP drop vs placebo** in the best modern trial (Sun 2016, 1.6 g × 12 weeks). Metabolic effects cluster at **1.5–3 g/day for ≥8 weeks** in people who already have T2D or MetS-range labs; HDL and body weight do not move. Isolated-taurine endurance effects are **small** (*g* ≈ 0.25–0.40), dose-insensitive from 1–6 g, and include clean nulls in trained cyclists. **It does not have human outcome evidence for longevity.** Singh 2023 is a strong **animal** lifespan / healthspan paper plus a human **association**. Fernandez 2025 and Marcangeli 2025 undercut the claim that circulating taurine universally falls with human age or tracks human muscle aging. TauAge (4 g × 6 months) is finished and unpublished. Mouse and monkey results are not a human aging result.